Everest Medicines Seeks Shareholder Approval for Strategic Cooperation Agreement With Hasten

PUBT · 1d ago
Everest Medicines Seeks Shareholder Approval for Strategic Cooperation Agreement With Hasten
  • Everest Medicines shareholders will vote November 16, 2026, on a strategic cooperation agreement with Hasten covering pharmaceutical distribution, manufacturing and commercialization.
  • Proposed payments to Hasten are capped at RMB 356 million for 2026, RMB 2.22 billion for 2027 and RMB 3.08 billion for 2028.
  • The agreement runs through December 31, 2028, with automatic three-year renewals subject to regulatory requirements.
  • Wei Fu, CBC Group and their relevant associates must abstain from voting because of their interests in the agreement.
  • The board and independent board committee recommend voting in favor of the agreement and related transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12390130), on October 30, 2026, and is solely responsible for the information contained therein.